Varun Chaudhary

Varun Chaudhary

Auto-generated profile, based on publicly available information

Varun Chaudhary

McMaster University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Eye
Verified
Journal Article
Closed access
PDF file
DRDaniel Rosenberg
Daniel Rosenberg
DDDeven M. Deonarain
Deven M. Deonarain
JGJonah Gould
Jonah Gould
ASAmirthan Sothivannan
Amirthan Sothivannan
MPMark R. Phillips
Mark R. Phillips
VCVarun Chaudhary
Varun Chaudhary

16 May 2025 in American Journal of Ophthalmology
Verified
Journal Article
Open access
MLMoiz Lakhani
Moiz Lakhani
Angela Kwan, MD, MScAngela Kwan, MD, MSc
Angela Kwan, MD, MSc
AMAndrew Mihalache
Andrew Mihalache
MPMarko M. Popovic
Marko M. Popovic
KNKeean Nanji
Keean Nanji
RMRajeev H. Muni
Rajeev H. Muni
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are important therapeutic options for type 2 diabetes and obesity; however, concerns about ophthalmic safety persist. This study examined associations between GLP-1 RAs and ocular adverse events (AEs). Global observational pharmacovigilance study. We searched the US FAERS database (via OpenVigil 2.1) and WHO's VigiBase (via VigiAccess) for optic nerve and retinal AEs associated with semaglutide and tirzepatide, covering the period from their respective approval dates-December 2017 for semaglutide and May 2022 for tirzepatide-through September 2024. In FAERS, all other drugs were compared, while in VigiBase, metformin, empagliflozin, dulaglutide, and insulin served as controls. Disproportionality metrics included reporting odds ratios (RORs) with 95% confidence intervals. Semaglutide and tirzepatide accounted for 76 444 cases (0.59%) in FAERS (n = 12 936 341) and 118 639 cases (0.34%) in VigiBase (n > 35 000 000). Semaglutide showed significantly higher odds of ischemic optic neuropathy (ION) (FAERS: ROR = 11.12, 95% CI = 8.15-15.16; VigiBase: ROR = 68.58, 95% CI = 16.75-280.67), diabetic retinopathy (DR) (FAERS: ROR = 17.28, 95% CI = 13.62-21.91; VigiBase: ROR = 7.81, 95% CI = 5.60-10.90), as well as retinal/vitreous detachment, retinal/vitreous hemorrhage, and retinal tear (FAERS: ROR = 2.44-5.89, 95% CI = 1.70-8.97, all P < .001, IC025 = 0.49, compared to all other drugs. VigiBase: ROR = 5.49-20.91, 95% CI = 2.71-90.11, all P ≤ .0001, IC025 ≥ 0.53, compared to metformin). Unique to VigiBase were macular edema (ROR = 3.87, 95% CI = 1.89-7.92), macular hole (ROR = 20.90, 95% CI = 2.65-165.01), and papilledema (ROR = 6.97, 95% CI = 2.53-19.17) (all P ≤ .004, IC025 ≥ 0.27, compared to metformin). Sensitivity analyses using empagliflozin and dulaglutide revealed significant associations with ION and DR, while vitreous detachment and hemorrhage were significant when compared to dulaglutide. Additionally, when insulin was used as a comparator, semaglutide showed a higher ROR for ION (ROR = 9.84, 95% CI = 4.25-22.81, P < .0001, IC025 = 0.42). However, tirzepatide was only significantly associated with DR in FAERS. Given the widespread use of semaglutide, its association with ocular AEs highlight the need for global pharmacovigilance and post-marketing surveillance.

5 January 2022 in Eye
Verified
Journal Article
Closed access
PDF file
YCYaping Chang
Yaping Chang
MPMark R. Phillips
Mark R. Phillips
RGRobyn Guymer
Robyn Guymer
LTLehana Thabane
Lehana Thabane
MBMohit Bhandari
Mohit Bhandari
TWTien Y. Wong
Tien Y. Wong

12 August 2021 in Retina
Verified
Journal Article
Open access
VCVarun Md Chaudhary
Varun Md Chaudhary
FMFrédéric Matonti
Frédéric Matonti
JZJavier MD Zarranz-Ventura
Javier MD Zarranz-Ventura
MSMichael W. Stewart
Michael W. Stewart
Purpose: Understanding the impact of fluid in different retinal compartments is critical to developing treatment paradigms that optimize visual acuity and reduce treatment burden in neovascular age-related macular degeneration. This systematic review aimed to determine the impact of persistent/new subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid on visual acuity over 1 year of treatment. Methods: Publication eligibility and data extraction were conducted according to Cochrane methods: 27 of the 1,797 screened records were eligible. Results: Intraretinal fluid negatively affected visual acuity at baseline and throughout treatment, with foveal intraretinal fluid associated with lower visual acuity than extrafoveal intraretinal fluid. Some studies found that subretinal fluid (particularly subfoveal) was associated with higher visual acuity at Year 1 and longer term, and others suggested subretinal fluid did not affect visual acuity at Years 1 and 2. Data on the effects of subretinal pigment epithelial fluid were scarce, and consensus was not reached. Few studies reported numbers of injections associated with fluid status. Conclusion: To optimally manage neovascular age-related macular degeneration, clinicians should understand the impact of fluid compartments on visual acuity. After initial treatment, antivascular endothelial growth factor regimens that tolerate stable subretinal fluid (if visual acuity is stable/improved) but not intraretinal fluid may enable patients to achieve their best possible visual acuity. Confirmatory studies are required to validate these findings.

1 April 2022 in Ophthalmology
Verified
Journal Article
Closed access
CFCarolina L.M. Francisconi
Carolina L.M. Francisconi
SMSamara B. Marafon
Samara B. Marafon
NFNatalia A. Figueiredo
Natalia A. Figueiredo
VJVerena R. Juncal
Verena R. Juncal
SSSufiyan Shaikh
Sufiyan Shaikh
RMRajeev H. Muni
Rajeev H. Muni

30 September 2021 in Eye
Verified
Journal Article
Closed access
PDF file
MPMark R. Phillips
Mark R. Phillips
PKPeter Kaiser
Peter Kaiser
LTLehana Thabane
Lehana Thabane
MBMohit Bhandari
Mohit Bhandari
VCVarun Chaudhary
Varun Chaudhary
TWTien Yin Wong
Tien Yin Wong